Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin: A Review in Type 1 Diabetes
Julia Paik, Hannah A. Blair
Drugs (2019) Vol. 79, Iss. 17, pp. 1877-1884
Open Access | Times Cited: 47

Showing 26-50 of 47 citing articles:

Quantitative computation and stability evaluation of phase III composition comprising sitagliptin and dapagliflozin propanediol monohydrate by RP-HPLC
Yesha Darshak Patel, Jigna Bhatt, Pinak Rameshbhai Patel, et al.
Journal of Applied Pharmaceutical Science (2022), pp. 148-155
Open Access | Times Cited: 3
Current Status of Dapagliflozin in Congestive Heart Failure
Gopal S Palandurkar, Sunil Kumar
Cureus (2022)
Open Access | Times Cited: 3
Truth in a pill
Shambo Samrat Samajdar, Shravan Venkatraman, Shashank Joshi, et al.
International Journal of Basic & Clinical Pharmacology (2024) Vol. 13, Iss. 3, pp. 408-412
Open Access
Expert opinion on fixed-dose combinations of sitagliptin + dapagliflozin and the triple drug combination of dapagliflozin + sitagliptin + metformin in the management of type 2 diabetes mellitus in Indian settings
Manjula Shantaram, Krishna Kumar M
International Journal of Advanced Research in Medicine (2024) Vol. 6, Iss. 2, pp. 31-35
Open Access
Nano Lipid Carrier System Development for Dapagliflozin: Central Composite Design Approach
Mallikarjun Vasam
Asian Journal of Pharmaceutics (2024) Vol. 18, Iss. 02
Open Access
Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients
Dongdong Wang, Cun Zhang, Ke Hu, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 1
Cardio-Renal Effects of SGLT2 Inhibitors in Diabetics and Non-Diabetics
Jennifer Matthews, Lakshini Y. Herat, Markus P. Schlaich, et al.
(2023)
Open Access | Times Cited: 1
Effect of dapagliflozin on blood glucose control, cardiac function, and myocardial injury markers in patients with type 2 diabetes and heart failure
Xin Liu, Yingxin Zhao
Tropical Journal of Pharmaceutical Research (2024) Vol. 23, Iss. 2, pp. 387-392
Open Access
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
Johan Jendle, Francisco Javier Ampudia‐Blasco, Martin Füchtenbusch, et al.
touchREVIEWS in Endocrinology (2021) Vol. 17, Iss. 1, pp. 12-12
Open Access | Times Cited: 3
Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice
Hiroshi Yaginuma, Ryoichi Banno, Runan Sun, et al.
Journal of Pharmacological Sciences (2021) Vol. 147, Iss. 4, pp. 340-347
Open Access | Times Cited: 3
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Anna Pietraszek
Current Drug Safety (2020) Vol. 16, Iss. 1, pp. 32-51
Closed Access | Times Cited: 2
Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function
Fei Ma, Jun Zhang, Huan Wang, et al.
Disease Markers (2022) Vol. 2022, pp. 1-6
Open Access | Times Cited: 1
USE OF SGLT2 INHIBITORS IN TYPE 1 DIABETES: EXPERIENCE FROM A PORTUGUESE TERTIARY CENTER
Mariana Aveiro-Lavrador, Bárbara Araújo, Miguel Melo, et al.
Revista Portuguesa de Endocrinologia Diabetes e Metabolismo (2023), Iss. 2
Open Access

Juanjuan Li, Ying Xin, Fang Wang, et al.
Pakistan Journal of Pharmaceutical Sciences (2023) Vol. 36, Iss. 1
Open Access
Evaluation of the Anti-Psoriatic Activity of Dapagliflozin and Levofloxacin Ointment on the Tail Mice
Waleed Khaled, Younis Al Bahadly, Ahlem Bdioui, et al.
Journal of Population Therapeutics and Clinical Pharmacology (2023) Vol. 30, Iss. 13
Open Access
Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes
Alicia J. Jenkins
Contemporary diabetes (2023), pp. 779-819
Open Access
Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
В. В. Соколов, Tatiana A. Yakovleva, Robert C. Penland, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access
Addressing potential pharmacological adverse reactions of dapagliflozin when taking along with other antidiabetics for the management of type 2 diabetes: A case report
Mohd Ajmal, Badruddeen Badruddeen, Ahmad Mukhtar, et al.
Annals of Phytomedicine An International Journal (2023) Vol. 12, Iss. 2
Open Access
Zastosowanie dapagliflozyny w terapii cukrzycy typu 1 u 36-letniej kobiety - opis przypadku
Katarzyna Rutkowska, Katarzyna Cypryk
Clinical Diabetology (2021)
Open Access
SODIUM-GLUCOSE LINKED COTRANSPORTER 2 INHIBITOR: A NEW HORIZON IN THE TREATMENT OF TYPE-2 DIABETES
Rekha Bisht
Asian Journal of Pharmaceutical and Clinical Research (2021), pp. 45-48
Open Access
Light-Mediated Cross-Coupling of Anomeric Trifluoroborates
Eric J. Miller, Maciej A. Walczak
(2021)
Open Access
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
Johan Jendle, Francisco Javier Ampudia‐Blasco, Martin Füchtenbusch, et al.
touchREVIEWS in Endocrinology (2021) Vol. 1, Iss. 1, pp. 12-12
Open Access
Previous Page - Page 2

Scroll to top